Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years

More than 40% of Japanese patients with multiple myeloma (MM) are over 75 years of age at diagnosis. Regardless of the treatment benefits, complications and relapses obstruct long-term survival. We conducted a phase II, open-label, single-arm, multicenter clinical trial to assess the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Akihiro, Kada, Akiko, Kagoo, Toshiya, Hidaka, Michihiro, Iida, Hiroatsu, Miyata, Yasuhiko, Saito, Akiko M., Sawamura, Morio, Komeno, Takuya, Sunami, Kazutaka, Takezako, Naoki, Nagai, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971029/
https://www.ncbi.nlm.nih.gov/pubmed/35392014
http://dx.doi.org/10.18999/nagjms.84.1.80

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971029/
https://www.ncbi.nlm.nih.gov/pubmed/35392014
http://dx.doi.org/10.18999/nagjms.84.1.80

Ejemplares similares